Navigation Links
No Causality Found Between Black Cohosh and Liver Problems
Date:5/5/2009

Results of a Randomized Study Presented at ACOG 2009 Annual Meeting Confirming Teschke's Re-evaluation of Spontaneous Reports

CHICAGO, May 5 /PRNewswire/ -- Black cohosh has been widely used in Europe and also in North America to treat menopausal symptoms including hot flashes, night sweats, occasional irritability and mood swings. While extensive research has been published on this botanical, the question of liver safety has arisen in a few isolated cases. Now, with the recent publication of Rolf Teschke, MD's re-evaluation of the four remaining cases held in question by the European Medicines Agency (EMEA), the suspicion of liver problems connected to black cohosh should be laid to rest.

This week, Belal Naser, MD, presented at the American College of Obstetricians and Gynecologists Annual Clinical Meeting in Chicago results of a placebo-controlled, double blind study. He concluded that the isopropanolic black cohosh extract (Remifemin(R)) has no effects on liver function. These findings are in agreement with Teschke's study published in Phytomedicine (2009; 16:72-84).

"Teschke's re-evaluation of the four 'remaining' cases considered by the European Medicines Agency (EMEA) as having a 'possible' or 'probable' causality, concluded that there was in fact no evidence for a causal relationship between treatment with black cohosh and the observed liver problems," explained Dr. Naser, Head of Drug Safety at Schaper & Brummer GmbH & Co. KG. This re-evaluation of case reports applied the latest qualitative and quantitative causality assessment and diagnostic algorithm of the Council for International Organizations of Medical Sciences (CIOMS).

"Due to incomplete data, the case of one patient was not assessable. In the remaining three cases, one patient diagnosed with autoimmune hepatitis had a favorable course under continued steroid therapy. The two other patients, who required liver transplants, received a final diagnosis of herpetic hepatitis. In none of these four was there any causality between treatment with black cohosh and liver disease," concluded Dr. Teschke.

"This analysis confirms our conclusion that these cases were, in general, insufficiently documented. More significantly, even the so-called 'well-documented cases' were debatable and little, if any, evidence remains that black cohosh (Cimicifugae racemosae rhizoma) can cause liver toxicity," said Dr. Naser.

Remifemin(R), manufactured by Schaper & Brummer GmbH & Co. KG in Germany is the most extensively researched form of black cohosh in the market--with 90 scientific papers and over 15 published studies establishing safety and efficacy. The present controlled study confirmed the safety of this botanical for the liver.


'/>"/>
SOURCE Remifemin
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
2. Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
3. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
4. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
5. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
6. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
7. AMA Foundation Announces Seed Grant Research Recipients
8. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
9. Parkinsons Disease Foundation Awards $300,000 in Bridge Funding for Innovative Research Projects
10. Inverseons Founder and SAB Member Published in PNAS
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
Breaking Medicine News(10 mins):